Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA)

CUSIP: 48301N104

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
17,734,228
Total 13F shares
174,435
Share change
-1,358,525
Total reported value
$123,288
Price per share
$0.71
Number of holders
9
Value change
-$1,296,527
Number of buys
8
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP 48301N104?
CUSIP 48301N104 identifies KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) as of Q2 2025

As of 30 Jun 2025, Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) was held by 9 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 174,435 shares. The largest 9 holders included XTX Topco Ltd, Aptus Capital Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA SECURITIES, LLC, HRT FINANCIAL LP, UBS Group AG, CITIGROUP INC, Tower Research Capital LLC (TRC), and BANK OF AMERICA CORP /DE/. This page lists 9 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.